

**DESCRIPTION**


<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse IGFBP-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human IGFBP-1, -2, -3, -4, -5, -6, recombinant mouse IGFBP-1, -3, -5, or -6 is observed.
<b>Source</b>	Monoclonal Rat IgG <sub>2A</sub> Clone # 150101
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant mouse IGFBP-2 Glu35-Gln305 Accession # CAA57270
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	Recombinant Mouse IGFBP-2 (Catalog # 797-B2) under non-reducing conditions only
<b>Neutralization</b>		Measured by its ability to neutralize IGFBP-2 inhibition of IGF-II-dependent proliferation in the MCF-7 human breast cancer cell line. Karey, K. P. <i>et al.</i> (1988) <i>Cancer Research</i> <b>48</b> :4083. The Neutralization Dose (ND <sub>50</sub> ) is typically 5-20 µg/mL in the presence of 0.75 µg/mL Recombinant Mouse IGFBP-2 and 30 ng/mL Recombinant Mouse IGF-II.

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

#### BACKGROUND

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Mouse IGFBP-2 cDNA encodes a 305 amino acid (aa) precursor protein with a 34 aa residue signal peptide and a 271 aa mature protein. Mouse and human IGFBP-2 share approximately 82% aa identity. IGFBP-2 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. During development, IGFBP-2 is expressed in a number of tissues. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system and in a number of reproductive tissues. IGFBP-2 binds preferentially to IGF-II, exhibiting a 2-10 fold higher affinity for IGF-II than for IGF-I.

#### References:

1. Jones, J.I. and D.R. Clemmons (1995) *Endocrine Rev.* **16**:3.
2. Kelley, K.M. *et al.* (1996) *Int. J. Biochem. Cell Biol.* **28**:619.
3. Schuller, A.G.P. *et al.* (1994) *Mol. Cell. Endoc.* **104**:57.
4. Landwehr, J. *et al.* (1993) *Gene* **124**:281.